Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

C4 Therapeutics (CCCC) Revenue: 2019-2025

Historic Revenue for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to $11.2 million.

  • C4 Therapeutics' Revenue fell 26.90% to $11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.1 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of $35.6 million for FY2024, which is 71.44% up from last year.
  • Per C4 Therapeutics' latest filing, its Revenue stood at $11.2 million for Q3 2025, which was up 73.76% from $6.5 million recorded in Q2 2025.
  • C4 Therapeutics' Revenue's 5-year high stood at $20.1 million during Q4 2021, with a 5-year trough of $2.7 million in Q2 2023.
  • For the 3-year period, C4 Therapeutics' Revenue averaged around $7.4 million, with its median value being $6.5 million (2025).
  • As far as peak fluctuations go, C4 Therapeutics' Revenue plummeted by 85.79% in 2022, and later surged by 350.68% in 2024.
  • Over the past 5 years, C4 Therapeutics' Revenue (Quarterly) stood at $20.1 million in 2021, then tumbled by 85.79% to $2.9 million in 2022, then increased by 14.26% to $3.3 million in 2023, then skyrocketed by 58.75% to $5.2 million in 2024, then decreased by 26.90% to $11.2 million in 2025.
  • Its Revenue stands at $11.2 million for Q3 2025, versus $6.5 million for Q2 2025 and $7.2 million for Q1 2025.